Lesch-Nyhan disease (LND) is a rare monogenic disease caused by deficiency of the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and is characterized by severe neuropsychiatric symptoms that currently cannot be treated. Predictive in vivo models are lacking for screening and evaluating candidate drugs because LNDassociated neurological symptoms are not recapitulated in HGPRT-deficient animals. Here, we used human neural stem cells and neurons derived from induced pluripotent stem cells (iPSCs) of children affected by LND to identify neural phenotypes of interest associated with HGPRT deficiency to develop a target-agnostic-based drug screening system. We screened more than 3000 molecules and identified 6 pharmacological compounds, all possessing an adenosine moiety, that corrected HGPRT deficiency-associated neuronal phenotypes by promoting metabolism compensations in an HGPRT-independent manner. This included Sadenosylmethionine (SAM), a compound that had already been used as a compassionate approach to ease the neuropsychiatric symptoms in LND. Interestingly, these compounds compensate abnormal metabolism in a manner complementary to the gold standard allopurinol and can be provided to LND patients via simple food supplementation. This experimental paradigm can be easily adapted to other metabolic disorders affecting normal brain development and functioning in the absence of a relevant animal model.
INTRODUCTION
Purines are both essential molecules for nucleic acid assembly and the most common carriers of chemical energy in mammalian cells. The cellular pool of purines is tightly maintained by the balance between their de novo synthesis, recycling and degradation (1). Mutations in enzymes of the synthesis or recycling pathways are accompanied by devastating neurological symptoms (2) . One of the most described purine-associated paediatric disorders is Lesch-Nyhan disease (LND), which is caused by deficiency of the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), an X chromosome-encoded protein (3) (4) . As a direct consequence, the recycling of guanine and hypoxanthine into guanosine mono-phosphate (GMP) and inosine mono-phosphate (IMP) is inefficient, leading to uric acid accumulation, formation of uric acid-containing kidney stones and finally renal failure. LND is also characterized by severe neuropsychiatric disorders described as choreoathetosis, dystonia, aggression, and self-injurious behaviour (5, 6) . Hyperuricemia and the formation of kidney stones can be controlled by the xanthine oxidase inhibitor 1,2-dihydro-4H-pyrazolo, pyrimidin-4-one (allopurinol, (7) .
Unfortunately, allopurinol treatment has no positive effect on neuropsychiatric symptoms (8) , and new pharmacological approaches are needed to control the neurological symptoms, specifically, that are associated with abnormal purine metabolism. However, the links between the metabolic derangements recorded in LND and the resulting neurological manifestations in children are still unknown. Neurological symptoms are not reproduced in genetic animal models of LND, while metabolic hallmarks are, indicating that either rodent brain cells develop alternative metabolic strategies that are not present in human cells, or that some purinedependent processes are not present during rodent brain development (9, 10) . In addition to these purely metabolic actions, purines activate a plethora of cell signalling pathways via membrane receptors that can act additively, synergistically or antagonistically (2) . Related to this mechanistic complexity, the precise measurement of purine intermediate concentrations requires complex techniques, such as HPLC, that are not easily amenable to "hard to access" tissues like the CNS. Consequently, most information that is collected is from peripheral cells.
However, purine metabolism in the brain, most particularly during development, appears to be different than in other organs, mainly relying upon recycling, with only reduced de novo synthesis activity recorded (11, 12) . From a genetic point of view, more than 400 mutations leading to a clinical phenotype have been identified, with a high degree of heterogeneity regarding their impact upon the enzyme activity. It remains, therefore, unclear whether the clinical phenotypes result from a reduced enzymatic activity toward hypoxanthine, guanine, or both (13, 14) . Together, this mechanistic complexity ultimately leads to abnormal brain function in LND, but the complexity compromises the development of pharmacological approaches using classical target-based strategies. In contrast, phenotypic-based assays monitor the existence of morphological and functional cellular phenotypes of interest that can discriminate between two experimental conditions in a target-agnostic manner. Phenotypic-based assays enable exploration of a much larger biological space by simultaneously probing the consequences of multiple and complex modifications of cellular events in their native environment and at endogenous levels. Here, we have used a phenotypic assay approach based on human induced pluripotent stem cells (iPSCs, 15) that are differentiated into neurons to study the impact of HGPRT deficiency. We previously showed that such neurons may be instrumental to identify potentially therapeutic pharmacological compounds using automated highthroughput drug screening coupled with image-based high-content analysis (HCA, [16] [17] [18] . In the current study, we show that LND cells demonstrate pathological changes during key steps of the differentiation of human PSC-derived neural stem cells (NSC) into cortical neurons.
Using this in vitro model, 6 compounds were identified from a collection of over 3000 tested compounds, suggesting paths for clinical development.
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RESULTS:
To develop a relevant model of LND amenable to drug screening, as a starting material, we used iPSCs reprogrammed from fibroblasts derived from children with LND to obtain HGPRTdeficient neural stem cells and neurons. Primary cultures of fibroblasts isolated from 2 LND individuals were reprogrammed in parallel with 2 controls using 4 transcription factors: Oct4, Sox2, c-Myc, and KLF4 (Table S1) (15) . All iPSC lines self-renewed as undifferentiated colonies with typical PSC morphology ( Figure S1 ) and expressed the pluripotency markers Oct-4 and SSEA-4 ( Figure S1 ) and TRA 1-81 and SSEA3 (Figure S1). The iPSC lines were differentiated into cortical neural stem cells (NSCs), as described in Boissart et al. (17) , and proliferated at a similar rate and homogeneously expressed the two neural markers SOX2 and Nestin, (Figure S2) . Western blot analysis of HGPRT protein content confirmed a complete absence of HGPRT expression in the 2 LND donors ( Figure 1A) . Accordingly, the enzyme was active after reprogramming in the control cells (CTL) and was inactive in cells derived from the 2 LND individuals ( Figure S2 ). This indicated that HGPRT loss of function mutations did not compromise fibroblast reprogramming or iPSC engagement into the neural lineage when phenocopying the enzymatic defect associated with LND.
Phenotypic characterization of differentiated neurons derived from HGPRT-deficient NSCs
The consequences of HGPRT deficiency during the differentiation of NSCs into fully differentiated post-mitotic neurons were analyzed. Neuronal differentiation was initiated from HGPRT-competent (CTL1 and CTL2) and HGPRT-deficient (LND1 and LND2) NSCs in medium that contained N2 and B27 (N2B27, 19); multi-parametric assays were conducted during the progression of differentiation from day 4 to day 14. Quantification of Ki67 antigen indicated a progressive decrease of cell proliferation between day 0 (seeding) and day 14, associated with a reduction of the percentage of SOX2-positive undifferentiated NSCs ( Figure   6 1B and D) in CTL cells. This was paralleled by an increase of the HuC/D-positive post-mitotic neuronal cell fraction (Figure 1B and E) . At day 14, the percentage of undifferentiated NSCs ranged from 50 to 60%, and the percentage of neurons ranged from 40 to 50%. No difference was detected in HGPRT-deficient cells regarding the kinetics or the rate of differentiation. An analysis of the neuronal subtypes indicated that the cultures were mainly composed of glutamatergic and GABAergic neurons expressing the markers of the superficial cortical layers, CUX1 and Brn2. HGPRT deficiency did not modify the neuronal subtypes or the proportion of the different types of neurons in the cultures ( Figure 1B , 1F and Figure S2 ). Very little cell death was measured during the differentiation process, with no difference between HGPRT-competent and HGPRT-deficient cells ( Figure 1C ). In these differentiation conditions, after 14 days, HGPRT-deficient cells produced a global neuronal network that was morphologically indistinguishable from that obtained with HGPRT-competent NSCs ( Figure   1B ).
We hypothesized that our culture conditions would mask dependency on the purine salvage pathway by providing different carbon resources compared to the physiologically available resources, thus allowing increased de novo synthesis. The hypoxanthine concentrations, measured using HPLC, were elevated in NSCs derived from the 2 LND donors and were compared to their control counterparts, suggesting a high rate of de novo synthesis not compensated for by downstream salvage ( Figure S3 ). Consequently, to reveal phenotypes that are dependent on purine recycling while excluding any potential bias introduced by the overactivation of de novo synthesis, the culture conditions were modified to include low-level inhibition of the de novo pathway. Azaserine, a potent glutamine amidotransferase inhibitor that blocks 2 limiting reactions in the de novo synthesis pathway, was added to the neuronal differentiation medium at either 0.5 or 2 µM, with 80 µM hypoxanthine provided as the principle substrate to the cells to stimulate HGPRT-dependent purine salvage ( Figure S3 ). 7 Azaserine was first added to the medium on day 1 of differentiation and was included thereafter with each medium change every other day. The amount of cell death was measured on days 3, 6 and 10 after initiating the treatment, corresponding to days 4, 7 and 11 of differentiation. At these concentrations, azaserine did not compromise the survival of CTL NSCs with efficient (Figure 2E and 2G) . The sum of modifications induced by azaserine treatment when started on day 5 of differentiation led to a decreased number of neurons produced by HGPRT-deficient NSCs at the two concentrations ( Figure 2F and 2G ). An analysis of the neuronal subtypes indicated that azaserine did not specifically affect one neuronal subtype but rather demonstrated toxicity toward both glutamatergic and GABAergic neurons ( Figure S3 ).
Identification of LND-relevant pharmacological compounds using target-agnostic highthroughput screening (HTS)
Target-agonistic HTS was used to generate an assay to discover pharmacological compounds that could rescue phenotypes related to HGPRT-deficiency. The selected drug screening readout was the cell viability after treating NSCs with azaserine from day 1, i.e., the most dramatic phenotype. The immunofluorescence-based Hoechst/PI used thus far was replaced by a luminescence-based method Cell-TiterGlo (CTG) that quantifies ATP content and is an integrated measure of both metabolism and cell death. Dose-response experiments were performed to determine the optimal azaserine concentration to be used ( Figure 3A) . One micromolar azaserine was chosen because it induced a strong decrease in the ATP content in the 2 LND NSC cultures but had no effect on the CTL cells. The screening workflow is summarized in Figure 3B . NSCs from LND1 were seeded into 384-well plates and treated with chemical compounds after 5 h. The next day, 1 µM azaserine was added to the medium. After 48 h, the ATP content was quantified using CTG. The Z' factor was calculated using 5 sister plates with cells treated with DMSO as a positive control (max value) and cells treated with azaserine as a negative control (min value). The mean Z' factor value was 0.84, which was defined as an excellent screening assay ( Figure 3C) . The Z' factor was -1.04 when Hoechst/IP was used as a read-out, which confirmed the better sensitivity of the CTG method in this 9 screening paradigm. A total of 3838 pharmacological compounds were screened, and a z-score > 2  was chosen as a selection criteria. After the primary screening, 29 compounds had a zscore > 2  at 5 or 10 µM ( Figure 3D and Table S3 ). After retesting in technical replicates, 7 compounds that consistently induced an increase of more than 10% of CTG signal compared to non-treated cells were selected. Five of those compounds were finally selected because they exhibited a dose-dependent effect with an EC50 below 13 µM ( Figure 3E ). All of these compounds shared a common structural core that contained an adenosine moiety ( Figure 3F) .
For further investigation, we also tested S-adenosylmethionine (SAM), a structural homologue of N6-methyladenosine. CTG signal quantifying ATP cellular content generally, dose-response experiments for the 6 compounds were performed using Hoescht as a read-out in order to refine the capacity of the molecules to rescue cell viability. All compounds confirmed their efficiency at restoring cellular viability in LND1 NSCs in the presence of 1 µM azaserine in a dosedependent manner and were within the same EC50 range (Figure S4 ).
Adenosine-like compound specificity
The 6 compounds were retested in cells with other genetic backgrounds. The same efficiency was found for NSCs from LND2, as well as for two different clones of the hESC line SA001 that had been HGPRT-deleted using CRISPR/Cas9 technology (Figure 4A, Figure S5 ). The assay was also repeated using a selection medium that contained aminopterin instead of azaserine as a de novo pathway inhibitor (HAT medium) to exclude any artefacts due to interactions of the compounds with azaserine. Aminopterin selectively induced cell death in LND NSCs in a dose-dependent manner (Figure S5) , and a dose of 0.06 µM aminopterin was used to further test compound specificity. The 6 compounds demonstrated a similar rescuing efficiency as when using azaserine (Figure 4B) . To exclude the possibility that the 6 compounds were solely nonspecific inhibitors of apoptosis, their efficiency was tested using rotenone, an inhibitor of mitochondria complex I that affects NSC survival independently of HGPRT status (Figure S5) . None of the 6 compounds exhibited neuroprotective activity in that experimental set-up ( Figure 4C ).
Mode of action of the adenosine-like compounds
The mechanism of action of the adenosine-like compounds was next explored. One hypothesis was that these compounds directly restored an HGPRT-like activity. The expression of HGPRT and of the HGPRT pseudogene PRTFDC1, as well as HGPRT-like enzymatic activity, were quantified after treating LND NSCs with each compound for 72 h. Neither HGPRT nor PRTFDC1 expression was modified ( Figure 5A) , nor did the compounds induce any detectable HGPRT-like enzymatic activity ( Figure 5B ).
Allopurinol was then tested to evaluate the possible contribution of xanthine oxidase inhibition.
This was not the case, since allopurinol did not rescue azaserine-treated LND NSCs ( Figure   5C ).
The contribution of the adenosine moiety to the compounds' mechanism of action was then evaluated. Adenosine was added 5 h after seeding the NSCs, and azaserine was added 24 h post seeding. Cell survival was quantified 72 h post seeding using Hoechst. SAM was used as a reference adenosine-like compound. In these conditions, adenosine-induced recovery was poor compared to SAM. The efficiency of recovery at maximal concentration for adenosine was 51.79 (+/-10.97%), compared to more than 130 +/-11.92 % for SAM. In addition, the EC90 for adenosine was 2.3*10 -3 , whereas the EC90 for SAM was 1.19*10 -5 . A second treatment with adenosine was added at the same time as azaserine in order to increase its bioavailability.
Adenosine remained less efficient than SAM (EC90adenosine: 1.43*10 -5 vs EC90SAM: 2.6*10 -6 , Figure 5D ). The same lack of efficiency was recorded when CTG was used as a read-out (EC90adenosine: 1.4*10 -3 vs EC90SAM: 5.4*10 -6 , Figure 5E ). Considering that the bioavailability of adenosine in vitro may not have been optimal, the contribution of the adenosine moiety of each compound to act as a source of AMP or inosine was assessed using an inhibitor of the adenosine kinase (ABT-702) or of the adenosine deaminase (pentostatin). ABT-702 totally blocked NAD+ and NADPH, while pentostatin increased the efficiency of NAD+ and NADPH ( Figure 5F and 5G) . Blocking the conversion of adenosine to inosine had no effect on SAM efficiency, while inhibiting its conversion into AMP decreased (but did not suppress) compound efficiency ( Figure 5H) . ABT-702 only had a partial blocking effect, while pentostatin increased A4pA efficiency ( Figure 5I) . Finally, the concentration of hypoxanthine and guanine was quantified by HPLC after NSC treatment with the compounds. ApA4 and NADPH normalized the levels of both purine metabolism products compared with the untreated LND NSCs. The 3 other compounds had no effect (Figure 5J and 5K) . (Figure 6B and 6F) , and increased the number of cells in azaserine-treated cultures (Figure 6C and 6F) . The percentage of HuC/D-positive cells and the total number of neurons produced was also increased, reaching levels similar to those observed for cells not exposed to azaserine (Figure 6D, 6E and 6F) . Analysis of neuronal subtypes in the culture treated with SAM suggested that both glutamatergic and GABAergic neurons were rescued by compound treatment (Figure S6) . Together, these findings indicated that by promoting adaptive metabolic strategies, all adenosine-like compounds ameliorated the cell survival, proliferation and differentiation rate of LND NSCs, and globally ameliorated neurogenesis in HGPRT-deficient cells (Figure 6F ).
Correction of LND-related neuronal phenotypes by adenosine-like compounds
DISCUSSION:
The main finding of this study is the establishment of a human model allowing the study of neurodevelopmental defects associated with metabolic disorders. This model enabled the highthroughput screening-based identification of pharmacological compounds with potential therapeutic action on LND neuropsychiatric symptoms. All identified compounds were adenosine donors, although the adenosine metabolic pathway only partially explained their efficiency at rescuing LND cells. This finding was obtained through a target-agnostic-based drug screening system thanks to the use of a pathological model based on neural cells differentiated from iPSC lines derived from patients affected by Lesch-Nyhan disease, along with an experimental paradigm that exploited the functional defects revealed by a specific culture medium.
The next step of this work would be to test the efficiency of the hit compounds in animal models of LND. HGPRT KO rodent models exhibit metabolic abnormalities consistent with deficient purine salvage (10, 20, 21) . In some extend, reduction of dopamine concentration in the caudateputamen nuclei was also reported both in mice and rats (20, 22) . Unfortunately, the rodent model failed to recapitulate the neuropsychiatric characteristics of LND, i.e., dystonia and selfinjurious behaviour (10, 20) . This lack of spontaneous neurobehavioral phenotype renders these models unsuitable for testing the efficacy of the compounds at a functional and integrated level. 13 Evidence of efficiency may therefore rely on human case reports. Indeed, the effect of SAM administration as a dietary supplement has been documented in some LND patients (23) (24) (25) (26) .
Due to these case reports, SAM supplementation was evaluated in 21 patients, including 18 with the full spectrum of LND-associated neuropsychiatric disorders. In most cases, supplementation with SAM led to a significant reduction in self-mutilation events and good clinical outcomes. However, Dolcetta and collaborators described aggravation of the symptoms or important adverse effects that some patients could not tolerate, leading the discontinuation of SAM. While encouraging, these reports described very different situations with high heterogeneity regarding the age of the patients (mainly adolescents and adults), the duration of the treatment, the dosage of SAM, the type of co-treatment and, finally, the type of benefit assessment. By demonstrating that SAM actually improved neuronal phenotypes that were directly associated with HGPRT-deficiency, our work advocates for a formal reassessment of supplementation with SAM as a beneficial complement in LND. Interestingly, two other compounds can be easily assessed in LND patients, because NAD and NADP can also be provided as food supplements.
Interestingly, all of the identified compounds possess at least one adenosine moiety in their structure. One hypothesis regarding their mode of action is that the release of adenosine can act to replenish adenosine in the cells, which can then be transformed into AMP by adenosine kinase, and then into ADP and ATP (27) . In addition, IMP can be formed from AMP by AMP deaminase and can then be converted to GMP in two reactions, mediated by IMP dehydrogenase, followed by GMP synthase. This constitutes a starting point to replenish GDP and GTP. Alternatively, adenosine can also serve as a source of inosine via the action of adenosine deaminase (28, 29) . We investigated the contribution of these two adenosinedependent pathways using ABT-702 or pentostatin to block the conversion of adenosine into AMP and inosine, respectively. In our experimental setup, ABT 702 totally or partially 14 abolished the efficacy of all the tested compounds at rescuing LND cells from azaserine treatment in a dose-dependent manner. In contrast, pentostatin increased the action of NAD, NADPH and A4p4 but had no effect upon SAM and N6M. Together, this demonstrated that the conversion of adenosine into AMP is one of the main modes of action of the compounds, with no contribution of the conversion into inosine. Interestingly, when tested in our paradigm, allopurinol did not provide any protection for azaserine-treated NSCs, indicating a mechanism of action of the adenosine-like compound that was different (and therefore complementary) to the so far gold standard treatment used to decrease uricemia in LND.
This study focused primarily on modelling LND neuronal phenotypes using the neural progeny of patient-derived iPSCs. We chose to differentiate iPSCs into cortical progenitors and neurons because this brain area is reported as functionally and anatomically abnormal in LND (30), (31) and because we previously showed that these cell types are fully amenable to high-throughput drug screening (16) . Lesch-Nyhan disease is considered a neurodevelopmental disorder with no signs of secondary neurodegeneration (6) . The conversion of NSCs into neurons represents a critical developmental period of vulnerability for the emergence of neurodevelopmental disorders (32); therefore, we chose to study the impact of purine deficiency from the very early stage of NSC conversion into neurons rather than on mature neurons only. We first differentiated the cells using the previously described neural medium N2B27, which did not reveal any alterations associated with HGPRT deficiency at the morphological level. HGPRT deficiency-associated phenotypes were only identified when azaserine, an inhibitor of HGPRT de novo synthesis, was added to the culture medium at concentrations that did not affect HGPRT-competent neural cells. This is in agreement with previous in vitro works by McKeran and collaborators that demonstrated the necessity of inhibiting the de novo pathway in cells to study HGPRT deficiency in order to re-create a "brain-like environment" (33) . In vitro, cells tend to increase the de novo synthesis to compensate for a recycling deficit, a situation that is 15 not physiologically possible in the brain where the de novo pathway enzymes are only poorly active (12) . This highlights the intrinsic ability of different cell types to mobilize alternative energy supplies to cope with bioenergetics stress-a property termed 'metabolic flexibility' (34, 35) . However, one caveat of our study is that it mainly relied upon morphological observations of the neuronal network. It would be of interest to compare LND and control cells with or without azaserine at a more functional level, for example by using microelectrode arrays or optical assays.
Overall, our study identified metabolic pathways in LND neural cells that can be relevant therapeutic targets to ease the devastating neuropsychiatric symptoms associated with this pathology. Interestingly, these pathways can be activated in LND patients via simple food supplementation. This also opens the door for larger screening studies of FDA-approved drugs or of collections of novel chemical entities. This experimental paradigm can also be easily adapted to other enzyme-associated neurological disorders that affect normal brain development.
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MATERIALS AND METHODS:
Neural cell differentiation
Four iPSC lines, reprogrammed from male fibroblasts obtained from the Coriell biorepository (Coriell Institute for Medical Research, Camden, NJ, USA), consisting of two control and two LND cell lines, were used in this study. The two LND lines were reprogrammed from fibroblasts of LND-affected children (GM2227 and GM23784), both presenting self-injurious behaviours. All cell line details are summarized in table 1. For clarity, the control and LND cells were noted as CTL and LND, respectively, as described in Table S1 Gladbach, Germany), supplemented with 1:100 penicillin/streptomycin (Gibco, Grand Island, NY, USA) and vitronectin (Invitrogen, Carlsbad, CA, USA) as a matrix. The medium was changed every day, and the cells were manually passaged once per week. Cell cultures were incubated in a 37°C humidified atmosphere with 5% CO2. The differentiation protocol into neural stem cells (NSCs) was previously published (17) . NSCs were cultured in N2B27 medium supplemented with recombinant human fibroblast growth factor-2 (10 ng/ml), epidermal growth factor (10 ng/ml) and brain-derived neurotrophic factor (20 ng/ml) (all from PeproTech, London, UK). Cell cultures were maintained in a humidified atmosphere of 5% CO2 at 37°C, and the medium was changed every other day. Terminal neuronal differentiation was induced by plating the cells in poly-ornithine/laminin-treated 384-well plates in N2B27 medium without growth factors. The medium was changed twice per week with the addition of laminin (1:500, Gibco) to avoid neuronal clumping. Neuronal differentiation was maintained at least 14 days and up to 18 days to obtain well-characterized cortical neurons. Table S2 ). The membranes were then washed 3 times with PBS-T and incubated for 1 h at RT with HRP-labelled secondary antibodies (GE-Healthcare, Little Chalfont, UK) at 1:10000 in blocking buffer. The signal was visualized by enhanced chemiluminescence using an Amersham ECL Plus Western Blotting Detection kit (GE Healthcare). Beta-actin at 1:50000 was used as a loading control.
Western blotting
HGPRT enzymatic activity
HGPRT activity was measured using a PRECICE HPRT Assay kit (Novocib, Lyon, France).
HGPRT activity was detected as the rate of production of inosine monophosphate (IMP) in the presence of α-D-5-phosphoribosyl-1-pyrophosphate (PRPP), followed by IMP oxidation with the reduction of NAD+ to NADH, measurable by the absorbance at 340 nm. PBS-washed cell pellets were resuspended in ice-cold water containing NP-40 lysis buffer (Thermo Scientific) and a protease inhibitor cocktail (Thermo Scientific); the samples were then sonicated at 4°C.
After centrifugation, the supernatants were collected to measure HGPRT activity following the manufacturer's instructions. The total protein content was determined using a Pierce BCA Protein Assay kit (Thermo Scientific). HGPRT kinetic activity in the cell lysates was measured over 3 hours by reading the absorbance at 340 nm, and enzymatic activity (nmol/mg of protein/hour) was calculated using a recombinant HGPRT enzyme as a standard.
High-throughput drug screening assay
To conduct high-throughput compound screening, NSCs were plated into polyornithine/laminin-treated 384-well plates at 5000 cells per well in N2B27 medium without antibiotics using the Biocel 1800 platform (Agilent Technologies, Santa Clara, CA, USA). 
Immunostaining and high-content image analysis
Cells were fixed using 4% PFA (Electron Microscopy Sciences, Hatfield, PA, USA) and incubated overnight at 4°C with primary antibodies (Table S2 ) diluted in a blocking buffer composed of 1X PBS, 1% BSA (Sigma) and 0.3% Triton X-100 (Sigma). The cells were washed three times in PBS and incubated for 45 min at RT with Alexa Fluor-conjugated secondary antibodies (Thermo Scientific). Finally, the cells were washed three times in PBS.
In addition, Hoechst 33228 (1:3000, Sigma) nuclear staining was performed during the secondary labelling. The fluorescence signal was detected using the high-content analysis system ImageXpress (Molecular Devices, San Jose, CA, USA). The apoptotic cell ratio during neuronal differentiation was determined using a Hoechst-PI staining assay. Living cells were treated with a mix of Hoechst 33228 (6 µg/ml, Sigma) and propidium iodide (0.4 µg/ml, Sigma) for 30 min at 37°C. The fluorescence signal was detected using an ImageXpress system (Molecular Devices).
Purine measurement by HPLC
NSCs were dissociated in trypsin (Gibco) and then washed one time in PBS. After centrifugation, whole-cell pellets were collected and snap-frozen in liquid nitrogen. They were then resuspended in cold water and sonicated at 4°C. The total protein concentration was measured using a Pierce BCA Protein Assay kit (Thermo Scientific). The cell lysates were treated with 1 M perchloric acid (Sigma) and incubated for 5 min at 40°C, followed by centrifugation at 10000 rpm at room temperature. The supernatants were collected and stored at -20°C. 
Genome editing using the CRISPR/Cas9 system
Indicators and statistics
To evaluate assay and automation robustness, the Z' factor was calculated in 5 sister plates as follows: Z' factor = 1-((3*σ max +3*σ min)/max-min), where σ is the standard deviation of positive controls (max) or negative controls (min), and μ is the mean signal value of positive and negative controls (37). In the survival experiments, NSCs treated with DMSO were considered as the positive control, and azaserine-treated NSCs served as the negative control.
The percentage of recovery induced by each pharmacological compound was calculated as follows: [(luminescence value of compound-treated well -median of azaserine only-treated wells)/(median value of DMSO only-treated wells -median of azaserine only-treated wells)]*100. 21 For the selection of positive compounds in primary screening, the Z-score (38) was calculated and was defined as Z =(x−μ)/σ, where x is the relative luciferase activity of an individual compound, μ is the mean luciferase activity of all test compounds, and σ is the standard deviation of all test compounds. Hit compounds were defined as those with a minimum Z-score of 2.0, meaning that its luciferase activity was two standard deviations above that of the mean.
ANOVA followed by the Holm-Sidak post hoc test was applied for intergroup multiple comparisons.
For dose-response experiments, nonlinear regression and calculation of the EC50 and EC90
values were performed using PRISM software (GraphPad, San Diego, CA, USA). 
